Answers are grounded in this paper and cite their sources.
To evaluate the overall survival (OS) of patients with chronic lymphocytic leukemia (CLL) receiving either ibrutinib monotherapy as a first-line (1L) treatment or chemotherapy/chemoimmunotherapy-based (CT/CIT) regimens in 1L followed by ibrutinib in the second line (1L CT/CIT-2L ibrutinib) after disease progression by emulating a randomized trial comparing both treatment sequences.
No takes yet. Share an insight, caveat, or question.
Robak et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: